-
2
-
-
0003964361
-
-
American Cancer Society American Cancer Society Atlanta Accessed: January 1, 2012
-
American Cancer Society Cancer facts and figures 2012 2012 American Cancer Society Atlanta http://www.cancer.org/Research/CancerFactsFigures/index Accessed: January 1, 2012
-
(2012)
Cancer Facts and Figures 2012
-
-
-
3
-
-
79958043675
-
-
Bethesda, MD: National Cancer Institute Accessed: January 1, 2012
-
N. Howlader, A.M. Noone, M. Krapcho SEER cancer statistics review, 1975-2008 Bethesda, MD: National Cancer Institute http://seer.cancer.gov/csr/ 1975-2008/ Accessed: January 1, 2012
-
SEER Cancer Statistics Review, 1975-2008
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
4
-
-
84859416222
-
Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008
-
R.L. Siegel, E.M. Ward, A. Jemal Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008 Cancer Epidemiol Biomarkers Prev 21 2012 411 416
-
(2012)
Cancer Epidemiol Biomarkers Prev
, vol.21
, pp. 411-416
-
-
Siegel, R.L.1
Ward, E.M.2
Jemal, A.3
-
5
-
-
80052965666
-
Is it time to lower the recommended screening age for colorectal cancer?
-
D.M. Davis, J.E. Marcet, J.C. Frattini Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg 213 2011 352 361
-
(2011)
J Am Coll Surg
, vol.213
, pp. 352-361
-
-
Davis, D.M.1
Marcet, J.E.2
Frattini, J.C.3
-
6
-
-
78649392125
-
The challenge of metastatic colorectal cancer
-
E.U. Cidón The challenge of metastatic colorectal cancer Clin Med Insights Oncol 4 2010 55 60
-
(2010)
Clin Med Insights Oncol
, vol.4
, pp. 55-60
-
-
Cidón, E.U.1
-
7
-
-
80052758962
-
Characterizing medical care by disease phase in metastatic colorectal cancer
-
X. Song, Z. Zhao, B. Barber Characterizing medical care by disease phase in metastatic colorectal cancer J Oncol Pract 7 2011 25S 30S
-
(2011)
J Oncol Pract
, vol.7
-
-
Song, X.1
Zhao, Z.2
Barber, B.3
-
8
-
-
67650315187
-
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial
-
T. André, C. Boni, M. Navarro Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial J Clin Oncol 27 2009 3109 3116
-
(2009)
J Clin Oncol
, vol.27
, pp. 3109-3116
-
-
André, T.1
Boni, C.2
Navarro, M.3
-
9
-
-
0015008620
-
Isolation of a tumor factor responsible for angiogenesis
-
J. Folkman, E. Merler, C. Abernathy Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 1971 275 288
-
(1971)
J Exp Med
, vol.133
, pp. 275-288
-
-
Folkman, J.1
Merler, E.2
Abernathy, C.3
-
10
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
11
-
-
36048960109
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
-
DOI 10.1200/JCO.2007.11.3357
-
C.S. Fuchs, J. Marshall, E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 2007 4779 4786 (Pubitemid 350086481)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.30
, pp. 4779-4786
-
-
Fuchs, C.S.1
Marshall, J.2
Mitchell, E.3
Wierzbicki, R.4
Ganju, V.5
Jeffery, M.6
Schulz, J.7
Richards, D.8
Soufi-Mahjoubi, R.9
Wang, B.10
Barrueco, J.11
-
12
-
-
0036984640
-
Role of angiogenesis in tumor growth and metastasis
-
J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 suppl 16 2002 15 18
-
(2002)
Semin Oncol
, vol.29
, Issue.SUPPL. 16
, pp. 15-18
-
-
Folkman, J.1
-
13
-
-
0141988568
-
Fundamental concepts of the angiogenic process
-
DOI 10.2174/1566524033479465
-
J. Folkman Fundamental concepts of the angiogenic process Curr Mol Med 3 2003 643 651 (Pubitemid 37236406)
-
(2003)
Current Molecular Medicine
, vol.3
, Issue.7
, pp. 643-651
-
-
Folkman, J.1
-
14
-
-
77953988924
-
Targeting the tumour vasculature: Insights from physiological angiogenesis
-
A.S. Chung, J. Lee, N. Ferrara Targeting the tumour vasculature: insights from physiological angiogenesis Nat Rev Cancer 10 2010 505 514
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 505-514
-
-
Chung, A.S.1
Lee, J.2
Ferrara, N.3
-
15
-
-
47949089077
-
VEGF targeted therapy: Mechanisms of anti-tumour therapy
-
L.M. Ellis, D.J. Hicklin VEGF targeted therapy: mechanisms of anti-tumour therapy Natl Rev 8 2008 579 591
-
(2008)
Natl Rev
, vol.8
, pp. 579-591
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
16
-
-
12344312042
-
Cellular abnormalities of blood vessels as targets in cancer
-
DOI 10.1016/j.gde.2004.12.005, PII S0959437X04001911, Oncogenes and Cell Proliferation
-
P. Baluk, H. Hashizume, D.M. McDonald Cellular abnormalities of blood vessels as targets in cancer Curr Opin Genet Dev 15 2005 102 111 (Pubitemid 40127638)
-
(2005)
Current Opinion in Genetics and Development
, vol.15
, Issue.1
, pp. 102-111
-
-
Baluk, P.1
Hashizume, H.2
McDonald, D.M.3
-
17
-
-
77950279550
-
Tumor microvasculature and microenvironment: Novel insights through intravital imaging in pre-clinical models
-
D. Fukumura, D.G. Duda, L.L. Munn Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models Microcirculation 17 2010 206 225
-
(2010)
Microcirculation
, vol.17
, pp. 206-225
-
-
Fukumura, D.1
Duda, D.G.2
Munn, L.L.3
-
18
-
-
30744479430
-
Angiogenesis in life, disease and medicine
-
DOI 10.1038/nature04478, PII NATURE04478
-
P. Carmeliet Angiogenesis in life, disease and medicine Nature 438 2005 932 936 (Pubitemid 43093958)
-
(2005)
Nature
, vol.438
, Issue.7070
, pp. 932-936
-
-
Carmeliet, P.1
-
19
-
-
2942590261
-
Vascular endothelial growth factor as a target for anticancer therapy
-
DOI 10.1634/theoncologist.9-suppl-1-2
-
N. Ferrara Vascular endothelial growth factor as a target for anticancer therapy Oncologist 9 suppl 1 2004 2 10 (Pubitemid 38747842)
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL.. 1
, pp. 2-10
-
-
Ferrara, N.1
-
20
-
-
30744449235
-
Angiogenesis as a therapeutic target
-
DOI 10.1038/nature04483, PII NATURE04483
-
N. Ferrara, R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974 (Pubitemid 43093963)
-
(2005)
Nature
, vol.438
, Issue.7070
, pp. 967-974
-
-
Ferrara, N.1
Kerbel, R.S.2
-
21
-
-
70450175957
-
Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules
-
A. Grothey, E. Galanis Targeting angiogenesis: progress with anti-VEGF treatment with large molecules Nat Rev Clin Oncol 6 2009 507 518
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 507-518
-
-
Grothey, A.1
Galanis, E.2
-
22
-
-
56749174211
-
FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?
-
C. Fischer, M. Mazzone, B. Jonckx FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8 2008 942 956
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 942-956
-
-
Fischer, C.1
Mazzone, M.2
Jonckx, B.3
-
23
-
-
0033047875
-
VEGFs, receptors and angiogenesis
-
DOI 10.1006/scbi.1998.0091
-
T. Veikkola, K. Alitalo VEGFs, receptors and angiogenesis Semin Cancer Biol 9 1999 211 220 (Pubitemid 29273837)
-
(1999)
Seminars in Cancer Biology
, vol.9
, Issue.3
, pp. 211-220
-
-
Veikkola, T.1
Alitalo, K.2
-
24
-
-
65349186800
-
Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
-
Q.S. Chu Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors Expert Opin Biol Ther 9 2009 263 271
-
(2009)
Expert Opin Biol Ther
, vol.9
, pp. 263-271
-
-
Chu, Q.S.1
-
25
-
-
58149190795
-
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
-
L.M. Ellis, D.J. Hicklin Pathways mediating resistance to vascular endothelial growth factor-targeted therapy Clin Cancer Res 14 2008 6371 6375
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6371-6375
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
26
-
-
4143136640
-
Vascular endothelial growth factor: Basic science and clinical progress
-
DOI 10.1210/er.2003-0027
-
N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611 (Pubitemid 39099316)
-
(2004)
Endocrine Reviews
, vol.25
, Issue.4
, pp. 581-611
-
-
Ferrara, N.1
-
28
-
-
0028870050
-
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
-
D. Shweiki, M. Neeman, A. Itin Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis Proc Natl Acad Sci U S A 92 1995 768 772
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 768-772
-
-
Shweiki, D.1
Neeman, M.2
Itin, A.3
-
29
-
-
79960037492
-
Tyrosine kinase receptor Flt/VEGFR family: Its characterization related to angiogenesis and cancer
-
M. Shibuya Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer Genes Cancer 1 2010 1119 1123
-
(2010)
Genes Cancer
, vol.1
, pp. 1119-1123
-
-
Shibuya, M.1
-
30
-
-
0027997863
-
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
-
J. Waltenberger, L. Claesson-Welsh, A. Siegbahn Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor J Biol Chem 269 1994 26988 26995 (Pubitemid 24332901)
-
(1994)
Journal of Biological Chemistry
, vol.269
, Issue.43
, pp. 26988-26995
-
-
Waltenberger, J.1
Claesson-Welsh, L.2
Siegbahn, A.3
Shibuya, M.4
Heldin, C.-H.5
-
31
-
-
0026702970
-
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
-
B.I. Terman, M. Dougher-Vermazen, M.E. Carrion Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem Biophys Res Commun 187 1992 1579 1586
-
(1992)
Biochem Biophys Res Commun
, vol.187
, pp. 1579-1586
-
-
Terman, B.I.1
Dougher-Vermazen, M.2
Carrion, M.E.3
-
32
-
-
0029006696
-
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
-
F. Shalaby, J. Rossant, T.P. Yamaguchi Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice Nature 376 1995 62 66
-
(1995)
Nature
, vol.376
, pp. 62-66
-
-
Shalaby, F.1
Rossant, J.2
Yamaguchi, T.P.3
-
33
-
-
70350445902
-
VEGF-B: A survival, or an angiogenic factor?
-
X. Li, C. Lee, Z. Tang VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr 3 2009 322 327
-
(2009)
Cell Adh Migr
, vol.3
, pp. 322-327
-
-
Li, X.1
Lee, C.2
Tang, Z.3
-
34
-
-
9244227572
-
Vascular endothelial growth factor B, a novel growth factor for endothelial cells
-
DOI 10.1073/pnas.93.6.2576
-
B. Olofsson, K. Pajusola, A. Kaipainen Vascular endothelial growth factor B, a novel growth factor for endothelial cells Proc Natl Acad Sci U S A 93 1996 2576 2581 (Pubitemid 26104389)
-
(1996)
Proceedings of the National Academy of Sciences of the United States of America
, vol.93
, Issue.6
, pp. 2576-2581
-
-
Olofsson, B.1
Pajusola, K.2
Kaipainen, A.3
Von Euler, G.4
Joukov, V.5
Saksela, O.6
Orpana, A.7
Pettersson, R.F.8
Alitalo, K.9
Eriksson, U.10
-
35
-
-
13144266696
-
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells
-
DOI 10.1073/pnas.95.20.11709
-
B. Olofsson, E. Korpelainen, M.S. Pepper Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells Proc Natl Acad Sci U S A 95 1998 11709 11714 (Pubitemid 28460479)
-
(1998)
Proceedings of the National Academy of Sciences of the United States of America
, vol.95
, Issue.20
, pp. 11709-11714
-
-
Olofsson, B.1
Korpelainen, E.2
Pepper, M.S.3
Mandriota, S.J.4
Aase, K.5
Kumar, V.6
Gunji, Y.7
Jeltsch, M.M.8
Shibuya, M.9
Alitalo, K.10
Eriksson, U.11
-
36
-
-
65549139264
-
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis
-
F. Zhang, Z. Tang, X. Hou VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis Proc Natl Acad Sci U S A 106 2009 6152 6157
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 6152-6157
-
-
Zhang, F.1
Tang, Z.2
Hou, X.3
-
37
-
-
0142120350
-
Evidence of a novel isoform of placenta growth factor (P1GF-4) expressed in human trophoblast and endothelial cells
-
DOI 10.1016/S0165-0378(03)00082-2
-
W. Yang, H. Ahn, M. Hinrichs Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells J Reprod Immunol 60 2003 53 60 (Pubitemid 37272295)
-
(2003)
Journal of Reproductive Immunology
, vol.60
, Issue.1
, pp. 53-60
-
-
Yang, W.1
Ahn, H.2
Hinrichs, M.3
Torry, R.J.4
Torry, D.S.5
-
38
-
-
0030050025
-
Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor
-
A. Sawano, T. Takahashi, S. Yamaguchi Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor Cell Growth Differ 7 1996 213 221 (Pubitemid 26049830)
-
(1996)
Cell Growth and Differentiation
, vol.7
, Issue.2
, pp. 213-221
-
-
Sawano, A.1
Takahashi, T.2
Yamaguchi, S.3
Aonuma, M.4
Shibuya, M.5
-
39
-
-
69549116791
-
PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance
-
A. Escudero-Esparza, T.A. Martin, M.L. Davies PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance Cancer Genomics Proteomics 6 2009 239 246
-
(2009)
Cancer Genomics Proteomics
, vol.6
, pp. 239-246
-
-
Escudero-Esparza, A.1
Martin, T.A.2
Davies, M.L.3
-
40
-
-
19244379078
-
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
-
DOI 10.1038/87904
-
P. Carmeliet, L. Moons, A. Luttun Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions Nat Med 7 2001 575 583 (Pubitemid 32448325)
-
(2001)
Nature Medicine
, vol.7
, Issue.5
, pp. 575-583
-
-
Carmeliet, P.1
Moons, L.2
Luttun, A.3
Vincenti, V.4
Compernolle, V.5
De Mol, M.6
Wu, Y.7
Bono, F.8
Devy, L.9
Beck, H.10
Scholz, D.11
Acker, T.12
Dipalma, T.13
Dewerchin, M.14
Noel, A.15
Stalmans, I.16
Barra, A.17
Blacher, S.18
Vandendriessche, T.19
Ponten, A.20
Eriksson, U.21
Plate, K.H.22
Foidart, J.-M.23
Schaper, W.24
Charnock-Jones, D.S.25
Hicklin, D.J.26
Herbert, J.-M.27
Collen, D.28
Persico, M.G.29
more..
-
41
-
-
79960111080
-
Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study
-
J.F. De Groot, K.R. Lamborn, S.M. Chang Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 29 2011 2689 2695
-
(2011)
J Clin Oncol
, vol.29
, pp. 2689-2695
-
-
De Groot, J.F.1
Lamborn, K.R.2
Chang, S.M.3
-
42
-
-
18744405611
-
-
Genentech Inc South San Francisco, CA
-
Avastin [package insert] 2009 Genentech Inc South San Francisco, CA
-
(2009)
Avastin [Package Insert]
-
-
-
43
-
-
84860825824
-
-
Imclone LLC Branchburg, NJ
-
Erbitux [package insert] 2012 Imclone LLC Branchburg, NJ
-
(2012)
Erbitux [Package Insert]
-
-
-
44
-
-
84860809709
-
-
Amgen Inc Thousand Oaks, CA
-
Vectibix [package insert] 2011 Amgen Inc Thousand Oaks, CA
-
(2011)
Vectibix [Package Insert]
-
-
-
45
-
-
35648941728
-
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
-
DOI 10.1200/JCO.2007.12.0949
-
L.B. Saltz, H.J. Lenz, H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the bond-2 study J Clin Oncol 25 2007 4557 4561 (Pubitemid 350035312)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.29
, pp. 4557-4561
-
-
Saltz, L.B.1
Lenz, H.-J.2
Kindler, H.L.3
Hochster, H.S.4
Wadler, S.5
Hoff, P.M.6
Kemeny, N.E.7
Hollywood, E.M.8
Gonen, M.9
Quinones, M.10
Morse, M.11
Chen, H.X.12
-
46
-
-
77955887676
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and Leukemia Group B (CALGB 80303)
-
H.L. Kindler, D. Niedzwiecki, D. Hollis Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and Leukemia Group B (CALGB 80303) J Clin Oncol 28 2010 3617 3622
-
(2010)
J Clin Oncol
, vol.28
, pp. 3617-3622
-
-
Kindler, H.L.1
Niedzwiecki, D.2
Hollis, D.3
-
47
-
-
77951296573
-
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
-
C.H. Barrios, M.C. Liu, S.C. Lee Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer Breast Cancer Res Treat 121 2010 121 131
-
(2010)
Breast Cancer Res Treat
, vol.121
, pp. 121-131
-
-
Barrios, C.H.1
Liu, M.C.2
Lee, S.C.3
-
48
-
-
84865243485
-
Overcoming resistance to antiangiogenic therapies
-
Epub 2012 Jul 6
-
S. Tejpar, H. Prenen, M. Mazzone Overcoming resistance to antiangiogenic therapies Oncologist 17 2012 1039 1050 Epub 2012 Jul 6
-
(2012)
Oncologist
, vol.17
, pp. 1039-1050
-
-
Tejpar, S.1
Prenen, H.2
Mazzone, M.3
-
49
-
-
84863888220
-
Combining antiangiogenics to overcome resistance: Rationale and clinical experience
-
V. Moreno Garcia, B. Basu, L.R. Molife Combining antiangiogenics to overcome resistance: rationale and clinical experience Clin Cancer Res 18 2012 3750 3761
-
(2012)
Clin Cancer Res
, vol.18
, pp. 3750-3761
-
-
Moreno Garcia, V.1
Basu, B.2
Molife, L.R.3
-
50
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
G. Bergers, D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
51
-
-
79954451405
-
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
-
F. Loupakis, C. Cremolini, A. Fioravanti Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer Br J Cancer 104 2011 1262 1269
-
(2011)
Br J Cancer
, vol.104
, pp. 1262-1269
-
-
Loupakis, F.1
Cremolini, C.2
Fioravanti, A.3
-
52
-
-
79960984152
-
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
-
J. Yao, X. Wu, G. Zhuang Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy Proc Natl Acad Sci U S A 108 2011 11590 11595
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 11590-11595
-
-
Yao, J.1
Wu, X.2
Zhuang, G.3
-
53
-
-
35548982639
-
Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
-
DOI 10.1016/j.cell.2007.08.038, PII S0092867407011014
-
C. Fischer, B. Jonckx, M. Mazzone Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels Cell 131 2007 463 475 (Pubitemid 350007692)
-
(2007)
Cell
, vol.131
, Issue.3
, pp. 463-475
-
-
Fischer, C.1
Jonckx, B.2
Mazzone, M.3
Zacchigna, S.4
Loges, S.5
Pattarini, L.6
Chorianopoulos, E.7
Liesenborghs, L.8
Koch, M.9
De Mol, M.10
Autiero, M.11
Wyns, S.12
Plaisance, S.13
Moons, L.14
Van Rooijen, N.15
Giacca, M.16
Stassen, J.-M.17
Dewerchin, M.18
Collen, D.19
Carmeliet, P.20
more..
-
54
-
-
75749096309
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
-
S. Kopetz, P.M. Hoff, J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
-
(2010)
J Clin Oncol
, vol.28
, pp. 453-459
-
-
Kopetz, S.1
Hoff, P.M.2
Morris, J.S.3
-
55
-
-
0037143764
-
VEGF-Trap: A VEGF blocker with potent antitumor effects
-
DOI 10.1073/pnas.172398299
-
J. Holash, S. Davis, N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398 (Pubitemid 34920936)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.17
, pp. 11393-11398
-
-
Holash, J.1
Davis, S.2
Papadopoulos, N.3
Croll, S.D.4
Ho, L.5
Russell, M.6
Boland, P.7
Leidich, R.8
Hylton, D.9
Burova, E.10
Ioffe, E.11
Huang, T.12
Radziejewski, C.13
Bailey, K.14
Fandl, J.P.15
Daly, T.16
Wiegand, S.J.17
Yancopoulos, G.D.18
Rudge, J.S.19
-
56
-
-
74949101370
-
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors
-
W.P. Tew, M. Gordon, J. Murren Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors Clin Cancer Res 16 2010 358 366
-
(2010)
Clin Cancer Res
, vol.16
, pp. 358-366
-
-
Tew, W.P.1
Gordon, M.2
Murren, J.3
-
57
-
-
84861382251
-
Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR)
-
June 25 Barcelona, Spain
-
Van Cutsem E, Tabernero J, Lakomy R, et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial (EFC10262-VELOUR). Paper presented at: Congress on Gastrointestinal Cancer. European Society for Medical Oncology (ESMO). June 25, 2011; Barcelona, Spain.
-
(2011)
Congress on Gastrointestinal Cancer. European Society for Medical Oncology (ESMO)
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
-
58
-
-
77958198446
-
Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer?
-
K. Jin, Y. Shen, K. He Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 12 2010 526 532
-
(2010)
Clin Transl Oncol
, vol.12
, pp. 526-532
-
-
Jin, K.1
Shen, Y.2
He, K.3
-
59
-
-
84876832098
-
-
Regeneron Pharmaceuticals, Inc./sanofi-aventis, U.S. LLC Bridgewater, NJ
-
Zaltrap [prescribing information] 2012 Regeneron Pharmaceuticals, Inc./sanofi-aventis, U.S. LLC Bridgewater, NJ
-
(2012)
Zaltrap [Prescribing Information]
-
-
-
60
-
-
36749040908
-
VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
-
DOI 10.1073/pnas.0708865104
-
J.S. Rudge, J. Holash, D. Hylton VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade Proc Natl Acad Sci U S A 104 2007 18363 18370 (Pubitemid 350210713)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.47
, pp. 18363-18370
-
-
Rudge, J.S.1
Holash, J.2
Hylton, D.3
Russell, M.4
Jiang, S.5
Leidich, R.6
Papadopoulos, N.7
Pyles, E.A.8
Torri, A.9
Wiegand, S.J.10
Thurston, G.11
Stahl, N.12
Yancopoulos, G.D.13
-
61
-
-
70349330817
-
VEGF Trap-eye for the treatment of neovascular age-related macular degeneration
-
J.A. Dixon, S.C. Oliver, J.L. Olson VEGF Trap-eye for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 18 2009 1573 1580
-
(2009)
Expert Opin Investig Drugs
, vol.18
, pp. 1573-1580
-
-
Dixon, J.A.1
Oliver, S.C.2
Olson, J.L.3
-
62
-
-
84865129521
-
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
-
N. Papadopoulos, J. Martin, Q. Ruan Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
-
(2012)
Angiogenesis
, vol.15
, pp. 171-185
-
-
Papadopoulos, N.1
Martin, J.2
Ruan, Q.3
-
63
-
-
74949119167
-
Phase i study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors
-
A.C. Lockhart, M.L. Rothenberg, J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
-
(2010)
J Clin Oncol
, vol.28
, pp. 207-214
-
-
Lockhart, A.C.1
Rothenberg, M.L.2
Dupont, J.3
-
64
-
-
0037143739
-
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
-
DOI 10.1073/pnas.172398399
-
E.S. Kim, A. Serur, J. Huang Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma Proc Natl Acad Sci U S A 99 2002 11399 11404 (Pubitemid 34920937)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.17
, pp. 11399-11404
-
-
Kim, E.S.1
Serur, A.2
Huang, J.3
Manley, C.A.4
McCrudden, K.W.5
Frischer, J.S.6
Soffer, S.Z.7
Ring, L.8
New, T.9
Zabski, S.10
Rudge, J.S.11
Holash, J.12
Yancopoulos, G.D.13
Kandel, J.J.14
Yamashiro, D.J.15
-
65
-
-
0037934449
-
Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
-
DOI 10.1073/pnas.1432908100
-
J. Huang, J.S. Frischer, A. Serur Regression of established tumors and metastases by potent vascular endothelial growth factor blockade Proc Natl Acad Sci U S A 100 2003 7785 7790 (Pubitemid 36760047)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.13
, pp. 7785-7790
-
-
Huang, J.1
Frischer, J.S.2
Serur, A.3
Kadenhe, A.4
Yokoi, A.5
McCrudden, K.W.6
New, T.7
O'Toole, K.8
Zabski, S.9
Rudge, J.S.10
Holash, J.11
Yancopoulos, G.D.12
Yamashiro, D.J.13
Kandel, J.J.14
-
66
-
-
78650378957
-
Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors
-
W. Lassoued, D. Murphy, J. Tsai Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors Cancer Biol Ther 10 2011 1326 1333
-
(2011)
Cancer Biol Ther
, vol.10
, pp. 1326-1333
-
-
Lassoued, W.1
Murphy, D.2
Tsai, J.3
-
67
-
-
84876850852
-
Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models
-
San Francisco, CA, October 2007:A13
-
M. Chiron, P. Vrignaud, P. Lejeune Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models AACR Meeting Abstracts 2007 San Francisco, CA, October 2007:A13
-
(2007)
AACR Meeting Abstracts
-
-
Chiron, M.1
Vrignaud, P.2
Lejeune, P.3
-
68
-
-
84876873394
-
Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel and gemcitabine results in greater antitumor activity in tumor-bearing mice
-
April 12-16 San Diego, CA. Abstract 1107
-
Lejeune P, Chiron M, Moigne RL, et al. Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel and gemcitabine results in greater antitumor activity in tumor-bearing mice. Presented at: the American Association for Cancer Research (AACR) Annual Meeting, April 12-16, 2008; San Diego, CA. Abstract 1107.
-
(2008)
American Association for Cancer Research (AACR) Annual Meeting
-
-
Lejeune, P.1
Chiron, M.2
Moigne, R.L.3
-
69
-
-
85019781927
-
Combination of aflibercept (VEGF Trap) and docetaxel produces increased antitumor effects associated with enhanced changes to tumor vasculature
-
April 17-21 Washington, DC. Abstract 5427
-
Abrahams C, Li B, Parveen A, et al. Combination of aflibercept (VEGF Trap) and docetaxel produces increased antitumor effects associated with enhanced changes to tumor vasculature. Presented at: the American Association for Cancer Research (AACR). Annual Meeting, April 17-21, 2010; Washington, DC. Abstract 5427.
-
(2010)
The American Association for Cancer Research (AACR). Annual Meeting
-
-
Abrahams, C.1
Li, B.2
Parveen, A.3
-
70
-
-
77958061434
-
Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models
-
D. Lal, J.A. Park, K. Demock Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models Mol Cancer Ther 9 2010 2737 2751
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2737-2751
-
-
Lal, D.1
Park, J.A.2
Demock, K.3
-
71
-
-
69249228874
-
A phase i dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results
-
abstract:3556 Accessed: September 15, 2012
-
S.A. Limentani, R. Just, A. Purdham A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results J Clin Oncol 26 suppl 2008 abstract:3556 www.asco.org Accessed: September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Limentani, S.A.1
Just, R.2
Purdham, A.3
-
72
-
-
77953674924
-
A phase i dose escalation (DE) and pharmacokinetics (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5-FU2) in patients with advanced solid tumors (STs)
-
abstract:3557 Accessed September 15, 2012
-
O. Rixe, C. Verslype, D. Khayat A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5-FU2) in patients with advanced solid tumors (STs) J Clin Oncol 26 suppl 2008 abstract:3557 www.asco.org Accessed September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Rixe, O.1
Verslype, C.2
Khayat, D.3
-
73
-
-
84858193113
-
Phase i dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors
-
N. Isambert, G. Freyer, S. Zanetta Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors Clin Cancer Res 18 2012 1743 1750
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1743-1750
-
-
Isambert, N.1
Freyer, G.2
Zanetta, S.3
-
74
-
-
77953667091
-
A phase i dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: Preliminary results
-
abstract:14539 Accessed: September 15, 2012
-
G. Freyer, P. Fumoleau, B. You A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: preliminary results J Clin Oncol 26 suppl 2008 abstract:14539 www.asco.org Accessed: September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Freyer, G.1
Fumoleau, P.2
You, B.3
-
75
-
-
69249228874
-
A phase i dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (gem) in patients (pts) with advanced solid tumors: Preliminary results
-
abstract:3558 Accessed: September 15, 2012
-
A. Patnaik, M. Pipas, L. Rosen A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (gem) in patients (pts) with advanced solid tumors: preliminary results J Clin Oncol 26 suppl 2008 abstract:3558 www.asco.org Accessed: September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Patnaik, A.1
Pipas, M.2
Rosen, L.3
-
76
-
-
84876824206
-
Phase i dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer
-
abstract:538 Accessed: September 15, 2012
-
K. Yamazaki, T. Yoshino, K. Yamaguchi Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer J Clin Oncol 29 suppl 2011 abstract:538 www.asco.org Accessed: September 15, 2012
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Yamazaki, K.1
Yoshino, T.2
Yamaguchi, K.3
-
77
-
-
36849005801
-
VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study
-
abstract:5508 Accessed: September 15, 2012
-
W.P. Tew, N. Colombo, I. Ray-Coquard VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study J Clin Oncol 25 suppl 2007 abstract:5508 www.asco.org Accessed: September 15, 2012
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.
-
-
Tew, W.P.1
Colombo, N.2
Ray-Coquard, I.3
-
78
-
-
54849433672
-
Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA)
-
abstract:7627 Accessed: September 15, 2012
-
E. Massarelli, V.A. Miller, N.B. Leighl Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA) J Clin Oncol 25 suppl 2007 abstract:7627 www.asco.org Accessed: September 15, 2012
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.
-
-
Massarelli, E.1
Miller, V.A.2
Leighl, N.B.3
-
79
-
-
84858336778
-
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
-
N. Colombo, G. Mangili, S. Mammoliti A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites Gynecol Oncol 125 2012 42 47
-
(2012)
Gynecol Oncol
, vol.125
, pp. 42-47
-
-
Colombo, N.1
Mangili, G.2
Mammoliti, S.3
-
80
-
-
81255185158
-
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
-
R.L. Coleman, L.R. Duska, P.T. Ramirez Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer Lancet Oncol 12 2011 1109 1117
-
(2011)
Lancet Oncol
, vol.12
, pp. 1109-1117
-
-
Coleman, R.L.1
Duska, L.R.2
Ramirez, P.T.3
-
81
-
-
84856509199
-
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study
-
W.H. Gotlieb, F. Amant, S. Advani Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 13 2012 154 162
-
(2012)
Lancet Oncol
, vol.13
, pp. 154-162
-
-
Gotlieb, W.H.1
Amant, F.2
Advani, S.3
-
82
-
-
55749102152
-
Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601
-
abstract:2020 Accessed: September 15, 2012
-
J.F. De Groot, P.Y. Wen, K. Lamborn Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 J Clin Oncol 26 suppl 2008 abstract:2020 www.asco.org Accessed: September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
De Groot, J.F.1
Wen, P.Y.2
Lamborn, K.3
-
83
-
-
67649262706
-
Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial
-
abstract:4027 Accessed: September 15, 2012
-
P. Tang, S.J. Cohen, G.A. Bjarnason Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial J Clin Oncol 26 suppl 2008 abstract:4027 www.asco.org Accessed: September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Tang, P.1
Cohen, S.J.2
Bjarnason, G.A.3
-
84
-
-
77957068007
-
A phase II study of aflibercept (VEGF Trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium
-
abstract 5591 Accessed: September 15, 2012
-
C. Townsley, H. Hirte, P. Hoskins A phase II study of aflibercept (VEGF Trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: a study of the Princess Margaret Hospital Phase II Consortium J Clin Oncol 27 suppl 2009 abstract 5591 www.asco.org Accessed: September 15, 2012
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Townsley, C.1
Hirte, H.2
Hoskins, P.3
-
85
-
-
77950182626
-
Phase II study of aflibercept (VEGF Trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin
-
abstract:9028 Accessed: September 15, 2012
-
A.A. Tarhini, S. Christensen, P. Frankel Phase II study of aflibercept (VEGF Trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin J Clin Oncol 27 suppl 2009 abstract:9028 www.asco.org Accessed: September 15, 2012
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Tarhini, A.A.1
Christensen, S.2
Frankel, P.3
-
86
-
-
77957756488
-
Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium trial
-
P. Twardowski, W.M. Stadler, P. Frankel Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium trial Urology 76 2010 923 926
-
(2010)
Urology
, vol.76
, pp. 923-926
-
-
Twardowski, P.1
Stadler, W.M.2
Frankel, P.3
-
87
-
-
77954428008
-
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung
-
N.B. Leighl, L.E. Raez, B. Besse A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung J Thorac Oncol 5 2010 1054 1059
-
(2010)
J Thorac Oncol
, vol.5
, pp. 1054-1059
-
-
Leighl, N.B.1
Raez, L.E.2
Besse, B.3
-
88
-
-
84858339404
-
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma A trial of the Princess Margaret Hospital, Chicago and California cancer phase II consortia
-
H.J. Mackay, R.J. Buckanovich, H. Hirte A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma A trial of the Princess Margaret Hospital, Chicago and California cancer phase II consortia Gynecol Oncol 125 2012 136 140
-
(2012)
Gynecol Oncol
, vol.125
, pp. 136-140
-
-
Mackay, H.J.1
Buckanovich, R.J.2
Hirte, H.3
-
89
-
-
84861327108
-
Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer
-
September 23-27 Stockholm, Sweden. Abstract 6LBA
-
Tabernero J, Van Cutsem E, Lakomy R, et al. Results from VELOUR, a phase 3 study of aflibercept versus placebo in combination with FOLFIRI for the treatment of patients with previously treated metastatic colorectal cancer. Paper presented at: 2011 European Multidisciplinary Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 6LBA
-
(2011)
2011 European Multidisciplinary Congress
-
-
Tabernero, J.1
Van Cutsem, E.2
Lakomy, R.3
-
90
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
DOI 10.1200/JCO.2006.09.6305
-
B.J. Giantonio, P.J. Catalano, N.J. Neropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson III, A.B.8
-
91
-
-
84866152751
-
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study)
-
abstract CRA3503 Accessed: September 15, 2012
-
D. Arnold, T. Andre, J. Bennouna Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study) J Clin Oncol 30 suppl 2012 abstract CRA3503 www.asco.org Accessed: September 15, 2012
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Arnold, D.1
Andre, T.2
Bennouna, J.3
-
92
-
-
81155126233
-
Aflibercept (VEGF-TRAP): The next anti-VEGF drug
-
M.W. Stewart Aflibercept (VEGF-TRAP): the next anti-VEGF drug Inflamm Allergy Drug Targets 10 2011 497 508
-
(2011)
Inflamm Allergy Drug Targets
, vol.10
, pp. 497-508
-
-
Stewart, M.W.1
-
93
-
-
77957072191
-
Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase i clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results
-
abstract:14540 Accessed: September 15, 2012
-
C. Verslype, J. Spano, E. Van Cusem Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): preliminary results J Clin Oncol 26 suppl 2008 abstract:14540 www.asco.org Accessed: September 15, 2012
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL.
-
-
Verslype, C.1
Spano, J.2
Van Cusem, E.3
|